Lorven Biologics Germany    
Home About us Mission Service Therapeutivs Food and Cosmetics
Bild about us



Green or sustainable chemistry has become the ‘need of time’ for the development of active pharmaceutical ingredients in everyday medical practice. Sustainable manufacturing through product and process innovation is highly desirable approach for pharma manufacturing in changing global scenarios and economies.

The benefits of new generation of medicines based on innovative bio-processes go beyond the individual healthcare to sustainable economy and environment resilience. In order to continue to successfully develop and produce new pharmaceuticals based on green chemistry and make them available to patients in Europe, Lorven Biologics Germany GmbH was founded in an exclusive partnership with Lorven Biologics Pvt. Ltd. India. We are a biotechnology company with a comprehensive portfolio of sustainable and innovative products and solutions for production of biologicals in efficient, cost-effective, and environmentally friendly way. 

Our Indian counterpart, Lorven Biologics Pvt. Ltd., is one of the few pioneers interlinking synthetic biology, modern biotechnology, and green chemistry for simplified and resource-efficient production of complex bio-therapeutics, and fermentation-based biologicals. With this integrating approach and the proprietary technology platform, Lorven Biologics Germany has stepped ahead to tackle the unmet global demand for affordable healthcare solutions. We deliver high quality Active Pharmaceutical Ingredients (API), peptide-based bio-similars, vaccine platforms, engineered proteins, and human mAbs from the existing product portfolio.

Besides this, the expertise and capacity of Lorven Biologics is offered as a contract-based service for development of time, resource, and cost-efficient processes for the fermentation-based production of any biological of customer’s choice. Our team consists of highly motivated and skilled scientists as well as competent technicians, using cutting-edge technologies with a fully automated manufacturing facility. Lorven Biologics has successfully completed prototype development and characterization of:

  • Therapeutic biosimilars including Liraglutide, Teriparatide, and Teduglutide
  • Pharmaceutical chemicals (API) like Sitagliptin, Phenylephrine, Pregabalin and Atorvastatin
  • Vaccine platforms like CRM-197

As Lorven Biologics Pvt. Ltd.'s marketing partner for Europe and with exclusive techno-commercial rights, Lorven Biologics Germany GmbH aims to offer the expertise and capacity in developing cost-efficient processes for the fermentation-based production of any biological product a customer may require.

In addition, Lorven Biologics Germany GmbH supplies recombinant proteins/peptides and other biologics from the existing product portfolio as required by customers in Europe at a competitive price and with guaranteed quality.


Dr. Amal Mukhopadhyay, Co-Founder and Managing Director

Biochemist and recognised scientist, specialising in endocrinology and biotechnology, with many years of experience in biotechnology R&D and proven leadership skills. Many years of experience in leading several healthcare and business development organisations, including as founder of Agelab Pharma and Elga Biotech.

Dr. Diksha Dani, Co-Founder and VP for Intellectual Properties

Scientist in the field of life sciences with a focus on applications. Trained and experienced also in intellectual property management, technology transfer and strategic innovation management. Experienced and skilled in building collaborative networks and strategic partnerships.

Dr. Venkataramana Mudili, Managing Director, Lorven Biologics India and Scientific Mentor for Lorven Biologics Germany

A leading biotechnologist of India with nearly two decades of experience in developing innovative processes for production of biomolecules ranging from API to nutraceuticals and pigment manufacturing. Received Andhra Pradesh Academy Young Scientist Award & Best Researcher awards at international and national forums. Has more than 70 research publications and 20 patents.

Petra Stegemann, Head Communication und Organization

Germanist and academic librarian with many years of experience in corporate communications including various social media as well as in organisation and office management in the scientific field.

Scientific Advisory Board  

Dr Bhuwnesh Agrawal, MD, MBA

Specialist in pharmacology and toxicology, clinical pharmacology and internal medicine
C-level executive with extensive multicultural experience in the healthcare industry, including life sciences, diagnostics, medical devices and pharmaceuticals in B2B and B2C. Excellent track record in management, strategy, business development, marketing and sales. Recognised for breakthrough innovation, creative ideas, effective process and turnaround management.


Prof. Dr Michael Hildebrand

Pharmacist, Pharmacologist
Prof. Hildebrand is an expert in various areas of drug research and development, with a focus on pharmacokinetics, bioanalytics, CMC, GXPs and formulation development. His scientific experience ranges from small molecules to biological and radiopharmaceutical drugs, conventional dosage forms and delivery systems (e.g. patches and intrauterine devices) and covers therapeutic areas such as CV, CNS, oncology, hormone therapy and immunology.


Dr Maharaj Kishen Sahib

Consultant Biotechnology Research
His achievements include founding and setting up the Biotechnology Research Centre at WOCKHARDT Ltd Mumbai, India. He led a research and development team for the successful development of biosimilars/vaccines/fermentation products, some of which have been commercialised.


  © Lorven Biologics Germany 2023   Contact   Imprint